The Value of Anatomic Staging and Other Prognostic Factors in Small Cell Lung Cancer Management: A View of European Studies.
AffiliationCancer Research Campaign Department of Medical Oncology, Christie Hospital & Holt Radium Institute, Manchester, England
MetadataShow full item record
AbstractThe need to include simple laboratory indices and performance status evaluation in treatment decision making has been shown by multivariate analyses. The conventional limited-stage extensive-stage division of prognostic groups no longer provides sufficient information. Indeed, some patients in the limited-stage group have a poor prognosis and about one quarter of patients in the extensive-stage group have a better prognosis when information from performance status and pretreatment biochemistry is taken into account. There is no rational clinical need for elaborate staging procedures, eg, computed tomography scanning or bone marrow examination, in the majority of patients with small cell lung cancer. Adequate information for defining prognostic groups can be obtained by using performance status, lactate dehydrogenase, and other biochemical tests such as sodium, alkaline phosphatase, and albumin. Thereby the cost to the patient of unnecessary burdensome investigations and to health care could both be reduced.
CitationThe Value of Anatomic Staging and Other Prognostic Factors in Small Cell Lung Cancer Management: A View of European Studies. 1995, 5 (1):19-26 Semin Radiat Oncol
JournalSeminars in Radiation Oncology
- Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging.
- Authors: Vincent MD, Ashley SE, Smith IE
- Issue date: 1987 Nov
- Staging and clinical prognostic factors for small-cell lung cancer.
- Authors: Argiris A, Murren JR
- Issue date: 2001 Sep-Oct
- [Prognostic factors in small cell lung cancer].
- Authors: Torun E, Fidan A, Cağlayan B, Salepçi T, Mayadağli A, Salepçi B
- Issue date: 2008
- Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase.
- Authors: Mall JW, Schwenk W, Philipp AW, Meyer-Kipker C, Mall W, Muller J, Pollmann C
- Issue date: 2002 Jun
- The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.
- Authors: Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S, Norweigian Lung Cancer Study Group.
- Issue date: 2003 Mar